Capitalized fee paid estimated useful life.

No definition available.

Name:	inva_CapitalizedFeePaidEstimatedUsefulLife
Namespace Prefix:	inva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Decrease to accumulated deficit.

+ References

No definition available.

+ Details

Name:	inva_DecreaseToAccumulatedDeficit
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Increase in deferred tax assets.

+ References

No definition available.

+ Details

Name:	inva_IncreaseInDeferredTaxAssets
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Increase to convertible notes.

+ References

No definition available.

+ Details

Name:	inva_IncreaseToConvertibleNotes
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of customers.

+ References

No definition available.

+ Details

Name:	inva_NumberOfCustomers
Namespace Prefix:	inva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduction to additional paid in capital

+ References

No definition available.

+ Details

Name:	inva_ReductionToAdditionalPaidInCapital
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	inva_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix:	inva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=inva_LaJollaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=inva_CustomerOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=inva_CustomerTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=inva_CustomerThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Customer	Jul. 20, 2022
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of customers \| Customer	3
Capitalized fees paid, estimated useful life	15 years
ASU 2020-06
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Decrease to accumulated deficit	$ 37.2
Reduction to Additional Paid in Capital	65.4
Increase in Deferred Tax Assets	$ 7.4
Theravance Respiratory Company, LLC
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Equity method investment ownership percentage		15.00%
Customer Concentration Risk \| Net Product Sales \| La Jolla [Member] \| Customer One
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	33.00%
Customer Concentration Risk \| Net Product Sales \| La Jolla [Member] \| Customer Two
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	29.00%
Customer Concentration Risk \| Net Product Sales \| La Jolla [Member] \| Customer Three
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	28.00%
Customer Concentration Risk \| Receivables from Net Product Sales \| La Jolla [Member] \| Customer One
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	23.00%
Customer Concentration Risk \| Receivables from Net Product Sales \| La Jolla [Member] \| Customer Two
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	37.00%
Customer Concentration Risk \| Receivables from Net Product Sales \| La Jolla [Member] \| Customer Three
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Concentration Risk, Percentage	37.00%
Two Thousand Twenty Five Notes [Member] \| ASU 2020-06
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Increase in convertible notes	$ 35.6
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| RELVAR/BREO
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Royalty rate for first level of annual global net sales (as a percent)	15.00%
Annual global sales level used to determine royalty rate	$ 3,000.0
Royalty rate for sales above first level of annual global net sales (as a percent)	5.00%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| ANORO \| Minimum
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Royalty rate for combination products (as a percent)	6.50%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| ANORO \| Maximum
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Royalty rate for combination products (as a percent)	10.00%